Aresus Pharma GmbH news
DERMAGO GmbH today announced the publication of an article by the research group of PD Dr. J. Eberle from Charité-Universitätsmedizin Berlin, Germany.
The article entitled “Inhibition of Cell Proliferation and Cell Viability by Sinecatechins in Cutaneous SCC Cells Is Related to an Imbalance of ROS and Loss of Mitochondrial Membrane Potential” was released in the peer-reviewed journal Antioxidants1
The complete publication can be found on the
In the financing round on Companisto, the pharmaceutical company DERMAGO GmbH received an investment commitment of just under 2 million euros within only a few weeks. More than 750 private investors participated in the pharmaceutical company, which has already launched 2 out of 3 reimbursable pharmaceuticals for international distribution on the market.
The pharmaceutical company has been developing and marketing generics for prescription medicines in the field of skin diseases. In ad
Aresus Pharma GmbH, a subsidiary of DERMAGO GmbH, announced today that clinical results on the efficacy of 5-10% Topical Sinecatechins (synonyms: “Polyphenon® E“, ”defined extract from green tea leaves“) Ointment for Postmenopausal Vestibulodynia1 were presented at the 2nd Congress on Women’s Health Innovations & Inventions in Tel Aviv on July 11-12th, 2022. Additionally, the poster had previously be
DERMAGO Group (“DERMAGO”), announced today that it has acquired with immediate effect all patents regarding the manufacture of the pharmaceutical ingredient Polyphenon® E, a defined extract from green tea leaves, from the Japanese patent holder Mitsui Norin. Synonyms for “Polyphenon® E” are “defined extract from green tea leaves” and “Sinecatechins”.
The patent family comprises patents on the composition as well as th
Skin Care Pharma GmbH, a company of Dermago Verwaltungs GmbH, announces that yet another milestone has been reached in the development and approval of Skinatan 1 mg/g Emulsion for cutaneous application with the active ingredient methylprednisolone aceponate (MPA). Upon receipt of the “End of Procedure” notification, the decentralized procedure (DCP) for Skinatan 1 mg/g Emulsion has been successfully completed for six European member states. Within the next few weeks, Skin Care Pha
Aresus Pharma GmbH, a company of DERMAGO Holding GmbH, announced today that the abstract “Inhibition of cell-proliferation and cell viability by Polyphenon E (Veregen) in cutaneous SCC cell lines” has been accepted as an e-poster short presentation at the 31st German Skin Cancer Congress.
In the study, the authors around PD Dr. Eberle and Prof. Dr. Stockfleth were able to demonstrate that Polyphenon E induces a concentration-dependent inhibition of cel
Aresus Pharma GmbH, a subsidiary of DERMAGO Verwaltungs GmbH, has announced today that Dr. Francisco Harrison left his position as Managing Director for personal reasons. Dr. Harrison was in charge of Aresus‘ medical-scientific division. Co-Managing Director, Mr. Sven Schimansky-Wabra, will be in charge of Aresus‘ business operations as sole Managing Director with immediate effect.
As Managing Director of an affiliate of Aresus, Dr. Harrison will remain associated with the